A shortcut through process development for CAR-T cell manufacturing
Sponsor
For clinicians who want to start manufacturing CAR T cells, setting up a cell manufacturing process and QC system that can be transferred to GMP-compliant standards is extremely challenging. The development of a viable protocol is time-consuming and expensive, and translating protocols into SOPs is complicated, often resulting in further delays and expenses.
Learn how the Cell Manufacturing Enabling Package (CMEP) can save you time on process development, allowing you to proceed to validation as soon as possible. Designed by experts, and tested through years of experience in the CliniMACS Prodigy® cell manufacturing facility, it has been developed to accelerate your path toward clinical manufacturing. Complementing this, a matching protocol for establishing flow-based QC of CAR T cells using the MACSQuant® Analyzer has also been developed. Join the webinar to learn more about how you can benefit from these new developments.
- Overcome common issues faced in CAR T cell manufacturing
- Establish methods for flow-based QC of CAR T cells
- Understand the steps following the CMEP
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Empowering patient care: in-process and quality control solutions for cellular therapies
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
